Advertisement

Global Cancer Care

A Year of Global Progress Against Cancer—and Persistent Challenges

Despite data from the latest edition of The Cancer Atlas showing that nearly half of cancer mortality worldwide is attributed to modifiable risk factors, cancer incidence and mortality rates continue to soar.1 Globally, approximately 19 million new cases of cancer, excluding nonmelanoma skin...

Genomics/Genetics

Inherited Variants in 16 Genes May Double the Risk of Multiple Primary Cancers

Individuals carrying a rare pathogenic variant in one of 16 cancer-associated genes were 1.9 times more likely to develop a single cancer and 2.6 times more likely to develop multiple primary cancers, according to the results of a genetic association study published in JAMA Oncology

These...

COVID-19

Could a Nasal Spray Help Protect Patients With Cancer Against COVID-19 Infection?

Use of a daily interferon-α nasal spray could significantly reduce the risk of COVID-19 infection among adult patients with cancer, according to the results of a multicenter, randomized trial published in Clinical Infectious Diseases

The results suggest that the nasal spray could be a potential...

Hematologic Malignancies

Can a Common Anti-inflammatory Drug Help to Control Progression of Clonal Hematopoiesis?

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published by Mohammadnia et al in JACC ...

Colorectal Cancer

Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation

A randomized controlled trial investigating the effect of providing personalized risk information to patients and their providers about the patient’s risk for advanced colorectal neoplasia has found no difference in screening uptake with either the personalized risk messages or provider...

Breast Cancer

New Report on Breast Reconstruction Preferences Among African American Women

For African American patients undergoing mastectomy, the risk of complications and the postoperative appearance of the breast are among the important drivers of preferences about breast reconstruction, according to a new report published by Shammas et al in Plastic and Reconstructive Surgery.

...

Breast Cancer

AI Shear Wave Elastography Model for Diagnosing Breast Cancer in BI-RADS 3 or 4 Masses

In a study (INSPiRED 006) reported in the Journal of Clinical Oncology, Cai et al found that an artificial intelligence–guided shear wave elastography (AI-SWE) model provided accuracy similar to expert reading of B-mode ultrasound in the diagnosis of breast cancer in women with Breast Imaging...

Breast Cancer

Model to Identify Patients With Clinical High-Risk Early Breast Cancer Who May Avoid Escalated Adjuvant Therapy

As reported in the Journal of Clinical Oncology, Bidard et al developed a model that may identify a subgroup of patients with clinical high-risk estrogen receptor (ER)-positive/HER2-negative early breast cancer who might derive no additional distant recurrence benefit from escalation of adjuvant...

Head and Neck Cancer

Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma

A single administration of autologous tumor-infiltrating lymphocyte cell therapy with lifileucel led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior...

Issues in Oncology

How the AI-Powered ASCO® Guidelines Assistant Is Improving Clinical Decision-Making

This past May, ASCO announced its collaboration with Google Cloud to launch the ASCO® Guidelines Assistant, a new interactive tool that allows clinicians to quickly access ASCO’s evidence-based clinical guidelines to facilitate critical clinical decision-making. Developed with Google Cloud’s Vertex ...

Breast Cancer
Survivorship

Study Shows That After Early Breast Cancer Diagnosis, Risk of a Second Cancer is Low

For individuals diagnosed with early breast cancer, the long-term risk of developing a second primary cancer is low—around 2% to 3% greater than the general population)—according to findings published by McGale et al in The BMJ.

The researchers say this information can help reassure many breast...

Colorectal Cancer

Addition of Sintilimab to Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer

In a Chinese single-center phase II trial (SPRING-01) reported in The Lancet Oncology, Tian et al found that the addition of the PD-1 inhibitor sintilimab to chemotherapy following short-course radiotherapy as part of total neoadjuvant treatment significantly improved the pathologic complete...

Cardio-oncology

IDO1 Inhibition Mitigates Diet-Induced Risk of Cancer-Associated VTE in Preclinical Models

Patients with cancer who have a diet high in tryptophan, or protein-rich foods, have an increased risk for developing cancer-associated venous thromboembolism, according to preclinical findings published in Blood Advances

This increased risk could potentially be mitigated by treatment with an...

Issues in Oncology

Public Awareness of HPV, HPV Vaccine, and the Association of HPV With Cancer

In a U.S. state-level study reported as a research letter in JAMA Oncology, Garg et al found that awareness of human papillomavirus (HPV), HPV vaccination, and the association between HPV infection and development of cancers was “overwhelmingly low.”

As stated by the investigators, “Each year, an...

Hematologic Malignancies

FDA Approves BTK Inhibitor for ITP

The U.S. Food and Drug Administration (FDA) has approved rilzabrutinib (Wayrilz), a Bruton’s tyrosine kinase (BTK) inhibitor, for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The approval was based on the pivotal LUNA ...

Skin Cancer
Issues in Oncology

Misconceptions Regarding Skin Cancer Risk in the United States

Investigators may have uncovered associations between the reported number of sunburns and sociodemographic characteristics as well as the prevalence of protective skin behaviors adopted by U.S. adults, according to a recent study published by Etzel et al in the American Journal of Lifestyle...

Skin Cancer

Advanced Refractory Melanoma: Addition of Tilsotolimod to Ipilimumab

As reported in the Journal of Clinical Oncology by Adi Diab, MD, and colleagues, the phase III ILLUMINATE trial showed adding the Toll-like receptor-9 agonist tilsotolimod to ipilimumab in patients with advanced refractory melanoma produced no benefit.

Study Details

Four hundred and eighty-one...

Issues in Oncology
Genomics/Genetics
Solid Tumors
Bladder Cancer
Skin Cancer
Lung Cancer

Novel Strategy May Enhance Sensitivity, Accuracy of Monitoring Cancer in Blood Samples

A whole-genome sequencing–based, error-corrected method for detecting cancer from blood samples could be more sensitive and accurate in monitoring disease status posttreatment among patients with cancer compared with prior methods, according to a recent study published by Cheng et al in Nature...

CNS Cancers
Skin Cancer
Lung Cancer
Immunotherapy

Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases

Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open.

Study Methods and Results

In this study,...

Skin Cancer
Genomics/Genetics

Can ctDNA Monitoring Help to Predict Melanoma Recurrence?

A new study showed that approximately 80% of patients with stage III melanoma who had detectable levels of circulating tumor DNA (ctDNA) before they started treatment to suppress their tumors went on to experience recurrence. Researchers also found that the disease returned more than four times...

Skin Cancer
Issues in Oncology

AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings

Artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers from digital images of tissue samples, according to new findings presented by Song et al at the 2025 American Association for Cancer Research (AACR)...

Skin Cancer

Survival Trends in Melanoma Brain Metastases: Update of Melanoma Graded Prognostic Assessment

In a study reported in Journal of Clinical Oncology, Sperduto and colleagues analyzed trends in survival associated with newly diagnosed melanoma brain metastases and updated the Melanoma Graded Prognostic Assessment (GPA).

Study Details

The study involved retrospective data from...

Skin Cancer
Genomics/Genetics

Use of Niraparib in Patients With Advanced Melanoma

Researchers may have uncovered early indications of the clinical benefit of niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair, according to a recent study published by Kim et al in JCO Precision Oncology.

Background

The U.S. Food and Drug...

Skin Cancer
Immunotherapy

Dual Immunotherapy May Improve Progression-Free Survival in Advanced Squamous Cell Carcinoma

The combination of avelumab and cetuximab may improve progression-free survival in patients with advanced cutaneous squamous cell carcinoma compared with avelumab alone, according to recent findings presented by Zandberg et al at the 2025 ASCO Annual Meeting (Abstract 6002) and simultaneously...

Skin Cancer
Genomics/Genetics
Immunotherapy

Inherited Genetic Differences May Predict Resistance to Immunotherapy in Metastatic Melanoma

Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine.

Background

The investigation revolved around mitochondrial haplogroups ...

Skin Cancer

Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma

In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared disease-free survival outcomes of adjuvant cemiplimab vs placebo in patients with high-risk cutaneous squamous cell carcinoma.

Study Details

In the trial, 415...

Skin Cancer

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to avelumab in patients with advanced cutaneous squamous cell carcinoma.

Study Details

In the U.S. multicenter trial, 57 evaluable patients were...

Skin Cancer

Four-Drug Induction Regimen Under Study in Advanced Melanoma With BRAF Mutation

In a phase II trial (EBIN) reported in The Lancet Oncology, Robert et al investigated the survival benefit of adding induction encorafenib/binimetinib to nivolumab/ipilimumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutation.

Study Details

In the open-label trial, 271...

Skin Cancer

Role of Mitochondrial Pathways in Melanoma Progression, Treatment Resistance

The most aggressive melanomas may hyperactivate two key processes in mitochondria, according to a novel study, and blocking these pathways with currently available drugs may eliminate melanoma cells, explained investigators. These findings were published by Kim et al in the journal Cancer.

...

Skin Cancer

Intratumoral BO-112 With Pembrolizumab in Anti–PD-1–Resistant Melanoma

In a Spanish-French phase II trial (SPOTLIGHT-203) reported in the Journal of Clinical Oncology, Márquez-Rodas et al investigated the combination of the intratumoral agent BO-112 and pembrolizumab for activity in patients with advanced anti–PD-1–resistant melanoma. BO-112 is a synthetic,...

Skin Cancer

RP1 Plus Nivolumab in Anti–PD-1–Resistant Advanced Melanoma

When combined with nivolumab, RP1 (vusolimogene oderparepvec), a genetically engineered herpes simplex virus type 1–based oncolytic immunotherapy, induced deep and durable systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to...

Skin Cancer

Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma

A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable melanoma, according to long-term findings from a phase II study published in the Journal of Clinical...

Skin Cancer

Extended Follow-up for Neoadjuvant and Adjuvant Relatlimab Plus Nivolumab in Resectable Melanoma

In an extended follow-up of a phase II trial reported in the Journal of Clinical Oncology, Burton et al examined outcomes with neoadjuvant and adjuvant relatlimab-rmbw plus nivolumab in patients with resectable melanoma. Relatlimab targets LAG3, while nivolumab targets PD-1.

Study Details

In the...

Skin Cancer

Pembrolizumab and De-escalation of Treatment in Resectable Cutaneous Squamous Cell Cancer

In an Australian phase II trial (De-Squamate) reported in the Journal of Clinical Oncology, Ladwa et al found that the use of pembrolizumab produced a high rate of clinical or pathologic complete response in patients with resectable cutaneous squamous cell cancer (cSCC), suggesting the potential to ...

Skin Cancer

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could reduce recurrence after definitive local therapy for patients who had high-risk features....

Skin Cancer

Treatment-Resistant Melanoma: Novel Checkpoint Inhibitor Combination

New research published by Phadke et al in the Journal for ImmunoTherapy of Cancer found that adding a third immune-targeting drug to existing therapies may help to shrink tumors in laboratory models of treatment-resistant melanoma.

Although immunotherapeutics have improved survival for many...

Skin Cancer

Nivolumab Plus RP1 Shows Durable Responses in Advanced Melanoma After PD-1 Inhibitor Resistance

Nivolumab in combination with RP1 (vusolimogene oderparepvec), a herpes simplex virus type 1–based oncolytic immunotherapy, showed activity in patients with advanced melanoma who experienced disease progression on standard anti‒PD-1‒based immunotherapy, according to findings from the phase I/II...

Skin Cancer
Gastrointestinal Cancer

Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types

Researchers have uncovered that cancer cells degrade protective nerve coverings, causing cancer-induced nerve injury that can lead to chronic inflammation and resistance to anti–PD-1 immunotherapy, according to findings published in Nature

In exploring the role of perineural invasion and...

Skin Cancer

Basal Cell Carcinoma: Early Research on a Novel Topical Fluorescent Imaging Technique

A topical fluorescent molecular contrast agent, PARPi-FL (a poly[adenosine diphosphate ribose] polymerase 1 [PARP1] inhibitor–targeted fluorescent contrast agent) detected basal cell carcinoma through intact skin in as little as 5 minutes in ex vivo human tissues, according to new preclinical...

Understanding Accelerated Aging in Survivors of Childhood Cancers

Each year in the United States, nearly 16,000 children and adolescents between the ages of birth and 19 are diagnosed with cancer.1 And although survival rates have greatly improved for many types of childhood cancers, with more than 8 in 10 children and adolescents surviving at least 5 years after ...

Pancreatic Cancer

Conversion of Unresectable Into Resectable Pancreatic Cancer: Chemoradiotherapy vs Chemotherapy

In a German phase III trial (CONKO-007) reported in the Journal of Clinical Oncology, Fietkau et al found that although adding chemoradiotherapy (CRT) to chemotherapy vs chemotherapy alone following induction therapy did not improve overall R0 resection rate in all patients with initially...

Gynecologic Cancers
Breast Cancer

Do Breast and Gynecologic Cancers Contribute to Job Resignation in Working Women?

In a matched-cohort study reported in JAMA Network Open, Iwakura et al found that women with breast or gynecologic cancer had a higher risk of job resignation compared with their unaffected counterparts, especially among those who were older, had lower income, or had a history of depression.

“These ...

Leukemia
Geriatric Oncology

Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With AML

Based on the results of a single-center phase II trial published by Bhatt et al in the American Journal of Hematology, pretreatment geriatric assessment in older adults with acute myeloid leukemia (AML) appeared to be feasible, to identify several functional impairments, to help guide the selection ...

Gastrointestinal Cancer

Gastrointestinal Tumor Microbes May Predict Prognosis and Therapeutic Response

Microbes inside cancerous tumors can influence the spread of disease and the effectiveness of treatment, and those roles make them appealing targets for new therapies. Tumor microbiota–based tools could also help identify high-risk patients and those most susceptible to metastases, and possibly be...

Survivorship
Cost of Care

Government Housing Assistance Linked to Reduced Medical Financial Hardship Among Cancer Survivors

Cancer survivors receiving government-subsidized rent were found to have a lower risk of experiencing financial hardships around medical expenses compared with those not receiving housing assistance, according to the results of a cross-sectional study published as a research letter in JAMA Network...

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

After 2 decades of practicing medicine across multiple disciplines and health systems, I’ve witnessed the dramatic transformation of patient-physician interactions, and none more dramatic than what I’m seeing in this era of artificial intelligence (AI) and its impact on cancer care. Early in my...

Issues in Oncology

Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country

Remarkable advances in treatments for cancer over the past 2 decades are enabling increased personalized care for patients with the disease. However, the growing complexity of treatment methods, including targeted therapy, immunotherapy, and advanced oral therapy, make it challenging for medical...

CNS Cancers

Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test

A novel, multianalyte test has been developed to identify central nervous system cancers from small samples of cerebrospinal fluid (CSF). In findings published in Cancer Discoverythe study authors reported that the test, called CSF-BAM, achieved a sensitivity of 81% and a specificity of 100%. 

...

Hepatobiliary Cancer

Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy

Patients with intermediate-stage hepatocellular carcinoma who received a vaccine of dendritic cells in addition to transarterial chemoembolization (TACE) and preconditioning cyclophosphamide experienced longer progression-free survival than those who received cyclophosphamide and TACE alone. The...

Symptom Management

Real-World Incidence and Management of Infusion-Related Reactions to Monoclonal Antibody Therapy

In a retrospective analysis published in JCO Oncology Practice, Smolders et al investigated the incidence and clinical course of infusion-related reactions among patients treated with at least one monoclonal antibody in routine practice. The study evaluated real-world data to compare observed...

Sarcoma

Mifamurtide Plus Chemotherapy for Nonmetastatic High-Grade Osteosarcoma

In a pooled analysis of the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) trials reported in the Journal of Clinical Oncology, Palmerini et al found evidence of activity with the addition of mifamurtide to chemotherapy in patients with nonmetastatic high-grade osteosarcoma...

Breast Cancer

Analysis Shows No Major Racial Differences in Somatic Mutations of Triple-Negative Breast Cancer

A landmark study of the tumor mutational landscape of African American women with triple-negative breast cancer revealed that the mutational profile was largely similar with that of Asian and non-Hispanic White women, except for the presence of TP53 mutations in almost all African American...

Issues in Oncology

Survey Finds Discordance Between Treatment Preferences and Clinical Care for Advanced Cancer

Patients with advanced cancer reported in survey responses that their treatment often focused on optimizing longevity over maintaining comfort and quality of life, despite their goals that prioritized the opposite, according to study results published in Cancer

Additionally, the findings...

Head and Neck Cancer

Lu-177 Dotatate in Progressive Metastatic Pheochromocytomas and Paragangliomas

In an interim analysis of a National Institutes of Health phase II study reported in the Journal of Clinical Oncology, Lin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) was active in progressive metastatic pheochromocytomas and paragangliomas (PPGLs).

As stated by the investigators,...

Gynecologic Cancers

Disparities in U.S. County–Level Cervical Cancer Screening Coverage Lead to Differences in Outcomes

In a study reported as a research letter in JAMA Network Open, Amboree identified U.S. counties with low or high cervical cancer screening coverage and associated risks of cervical cancer incidence and mortality.

As stated by the investigators, “Recent research shows that cervical cancer incidence ...

Issues in Oncology

Association of Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms in Childhood Cancer Survivors

In an analysis from the Children’s Oncology Group ALTE03N1 Study reported in the Journal of Clinical Oncology, Zhou et al found a fourfold increased risk of subsequent neoplasms (SNs) among childhood cancer survivors with germline pathogenic/likely pathogenic (P/LP) mutations.

Study Details

The...

Gastroesophageal Cancer

Pembrolizumab Plus Chemotherapy vs Chemotherapy in Advanced Gastric Cancers: Final Survival Analysis From KEYNOTE-585

As reported in the Journal of Clinical Oncology by Shitara et al, the final overall survival analysis from the phase III KEYNOTE-585 study showed a numeric—but statistically nonsignificant—benefit with pembrolizumab plus chemotherapy vs chemotherapy in perioperative therapy for patients with...

What We Wish We Knew During Fellowship

July marks a significant transition for many professionals, particularly those beginning structured training programs on July 1. This article is designed to support new and current hematology-oncology fellows and trainees in making the most of their training experience. Although not all suggestions ...

ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR

ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

The ASCO-sponsored TAPUR study is a...

Issues in Oncology

Can Baseline Kidney Function Predict Chronic Kidney Disease After Cisplatin Treatment?

A population-based prognostic study published in JAMA Oncology found cisplatin treatment to be associated with a predictable decrease in the estimated glomerular filtration rate. According to Grant et al, their findings place patients with lower baseline kidney function at the highest risk for...

Breast Cancer
Survivorship

BWEL Weight-Loss Trial Reports Success for Patients With Breast Cancer at 1-Year Mark

Patients with stage II or III breast cancer who participated in a remote weight-loss intervention program lost an average of 4.7% of their baseline body weight after 1 year, whereas those in the education-only control group gained an average 1% of their baseline weight, according to a recent report ...

Colorectal Cancer

Two ACS Studies Show Colorectal Cancer Screening and Early Diagnosis Have Soared in Adults Aged 45 to 49 Years

It has been widely reported that colorectal cancer incidence has been increasing among younger adults under age 50 since the mid-1990s, with a consistent annual increase of 2% among adults aged 20 to 39. This increase prompted the American Cancer Society (ACS), in 2018, and the United States...

Hepatobiliary Cancer

Which First-Line Systemic Therapy Balances Survival and Quality of Life in Advanced Hepatocellular Carcinoma?

A network meta-analysis reported in JAMA Oncology found that among first-line systemic therapy options, immunotherapy-based combinations—particularly atezolizumab plus bevacizumab—offered the most favorable therapeutic balance between survival benefit and quality-of-life preservation in...

Symptom Management

Factors Influencing Symptom Burden in Pediatric Patients With Cancer: Insights From Routine Screening

As pediatric cancer survival rates continue to improve, attention has shifted to quality of life and symptom management. While a majority of patients experience problematic symptoms during treatment, these symptoms usually go undocumented and untreated. In a secondary analysis of a cluster...

Breast Cancer

Adding Everolimus to Chemotherapy Reduces Risk for Advanced Triple-Negative Breast Cancer

The addition of everolimus to standard carboplatin chemotherapy led to a 52% reduction in the risk of disease progression or death compared with carboplatin alone in patients with advanced triple-negative breast cancer, according to the results of a randomized phase II trial published in Breast...

Issues in Oncology

Unmet Social Needs Distort Trust in Cancer Information, Study Shows

Researchers have found that unmet social needs was associated with less trust in cancer information received from doctors and the health-care system, according to study findings led by the American Cancer Society and published in Psycho-Oncology

“Public trust in health authorities is so...

Sarcoma

Standard vs Histology-Tailored Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma

In an expanded cohort of a European trial reported in the Journal of Clinical Oncology, Alessandro Gronchi, MD, and colleagues found that histology-tailored neoadjuvant chemotherapy with trabectedin was noninferior in terms of disease-free survival to standard neoadjuvant anthracycline/ifosfamide...

Sarcoma
Immunotherapy
Cardio-oncology

Immunotherapy Outcomes in Patients With Primary Cardiac Soft-Tissue Sarcomas

In a U.S. multicenter retrospective analysis reported in JACC: CardioOncology, Amin H. Nassar, MD, and colleagues found that immune checkpoint inhibition resulted in mostly moderate activity in patients with primary cardiac soft-tissue sarcomas.

Study Details

The study included 24 patients with ...

Sarcoma
Immunotherapy

Neoadjuvant Immunotherapy May Improve Long-Term Survival in Patients With Resectable Soft-Tissue Sarcoma

Patients with soft-tissue sarcoma treated with neoadjuvant immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to phase II trial results published by Roland et al in Nature Cancer.

Background

About 13,000 new cases of soft-tissue...

Sarcoma

Nab-sirolimus in Advanced Malignant Perivascular Epithelioid Cell Tumors: AMPECT Trial Final Analysis

As reported in the Journal of Clinical Oncology by Wagner et al, final analysis of the phase II AMPECT trial has shown a median duration of response of more than 3 years in patients with advanced malignant perivascular epithelioid cell tumors treated with nab-sirolimus.

The primary analysis of the ...

Sarcoma
Immunotherapy

T-Cell Therapy in Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

In a phase II trial (SPEARHEAD-1) reported in The Lancet, D’Angelo et al found that the T-cell therapy afamitresgene autoleucel showed activity in patients with previously treated HLA-A*02 and MAGE-A4–expressing advanced synovial sarcoma or myxoid round cell liposarcoma.

As related by the...

Sarcoma

Doublet for Previously Treated Patients With Advanced Leiomyosarcoma

In a phase Ib study reported in the Journal of Clinical Oncology, Van Tine et al established the recommended phase II dose of oral unesbulin in combination with dacarbazine for patients with locally recurrent, unresectable or metastatic, relapsed or refractory leiomyosarcoma.

Unesbulin is a small...

Sarcoma
Immunotherapy

Can Pembrolizumab Improve Outcomes in Soft-Tissue Sarcoma?

The PD-1 inhibitor pembrolizumab may offer benefit in patients with soft-tissue sarcoma, according to recent findings presented by Mowery et al at the 2024 ASCO Annual Meeting (Abstract 11504).

Background

Soft-tissue sarcoma is a rare type of cancer affecting muscles, fat, and other connective...

Sarcoma
Solid Tumors
Issues in Oncology

Can FAP-Targeted Radioligand Therapy Benefit Patients With Advanced Sarcomas?

Fibroblast activation protein (FAP)-targeted radioligand therapy may be safe and effective in patients with progressive metastatic tumors, particularly advanced sarcomas, according to new findings presented by Lanzafame et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI)...

Sarcoma

Previously Untreated Intermediate-Risk Rhabdomyosarcoma: Addition of Temsirolimus to Chemotherapy in Young Patients

As reported in The Lancet Oncology by Gupta et al, the phase III Children’s Oncology Group ARST1431 trial showed no event-free survival benefit with the addition of temsirolimus to chemotherapy in previously untreated children, adolescents, or young adults with intermediate-risk rhabdomyosarcoma.

...

Sarcoma

FDA Grants Accelerated Approval to T-Cell Therapy for Unresectable or Metastatic Synovial Sarcoma

On August 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have ...

Sarcoma
Solid Tumors

Survival Outcomes With Addition of Trabectedin to Docetaxel in Leiomyosarcoma

As reported in The New England Journal of Medicine by Pautier et al, the French Sarcoma Group phase III LMS04 trial showed that the addition of trabectedin to doxorubicin significantly improved progression-free and overall survival in the first-line treatment of unresectable or metastatic uterine...

Sarcoma

Impact of Whole-Lung Irradiation in Newly Diagnosed Rhabdomyosarcoma With Lung Metastases

In a retrospective analysis from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group (COG) reported in the Journal of Clinical Oncology, Luo et al found that whole-lung irradiation (WLI) was associated with significantly better event-free survival vs no WLI in patients with newly...

Sarcoma

Addition of Lenvatinib to Ifosfamide/Etoposide in Children and Young Adults With Relapsed Osteosarcoma

In a phase II study (OLIE) reported in JAMA Oncology, Gaspar et al found that the addition of lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival in children or young adults with relapsed or refractory osteosarcoma.

Study Details

In the global open-label...

Sarcoma

Addition of Pembrolizumab to Radiation Therapy and Surgery in Stage III Soft-Tissue Sarcoma of the Extremity

In a phase II trial (SU2C-SARC032) reported in The Lancet, Mowery et al found that the addition of perioperative pembrolizumab to preoperative radiation therapy and surgery improved disease-free survival in patients with stage III soft-tissue sarcoma of the extremity.

Study Details

In the...

Sarcoma

Larotrectinib in Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors

In a Children’s Oncology Group study (ADVL1823) reported in Journal of Clinical Oncology, Laetsch et al found that larotrectinib was highly active in patients with newly diagnosed infantile fibrosarcoma and other pediatric NTRK fusion–positive solid tumors.

Study Details

The U.S. multicenter...

Sarcoma

Discontinuation and Resumption of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors

As reported in the Journal of Clinical Oncology by Mascarenhas et al, follow-up of a cohort of pediatric patients with TRK fusion sarcomas and related mesenchymal tumors treated with larotrectinib showed that discontinuation of treatment—with resumption for progressive disease—was associated with...

Sarcoma

Botensilimab Plus Balstilimab in Relapsed or Refractory Metastatic Sarcomas

In a phase Ib study reported in the Journal of Clinical Oncology, Wilky et al found that the combination of botensilimab (Fc-enhanced anti–CTLA-4 antibody) and balstilimab (anti–PD-1 antibody) yielded activity in patients with relapsed or refractory metastatic sarcomas.

Study Details

In the...

Sarcoma

High-Risk Rhabdomyosarcoma: Long-Term Outcomes With Maintenance Chemotherapy

As reported in the Journal of Clinical Oncology by Gianni Bisogno, MD, PhD, and colleagues, long-term follow-up of the European Paediatric Soft Tissue Sarcoma Study Group RMS2005 trial showed significant survival advantages with the use of maintenance chemotherapy in pediatric patients with...

Sarcoma

Rescue Therapy for Newly Diagnosed High-Grade Osteosarcoma

In a Japanese trial (JCOG0905) reported in the Journal of Clinical Oncology, Hiraga et al found no disease-free survival benefit with the addition of a higher dose of ifosfamide to methotrexate, doxorubicin, and cisplatin (MAP) in patients with newly diagnosed high-grade osteosarcoma with poor...

Sarcoma
Issues in Oncology

AACR 2025: AI-Driven Analysis of Digital Pathology Images May Improve Sarcoma Subtyping Among Pediatric Patients

A novel artificial intelligence (AI)-based model could accurately classify sarcomas among pediatric patients using digital pathology images alone, according to new findings presented by Thiesen et al at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Abstract 2423/8).

...

Solid Tumors
Sarcoma

Spatial Transcriptomics Identifies Novel Subtypes Associated With Disease Prognosis in Leiomyosarcoma

Patients with leiomyosarcoma experience a high risk of recurrence and have limited treatment options. No biomarkers or targetable mutations currently improve diagnosis, prognosis, or treatment. Spatial transcriptomics, which are rarely used in sarcomas, may provide insights into leiomyosarcoma...

Lung Cancer

Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC

“Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB non–small cell lung cancer [NSCLC],” according to Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and ...

Gastrointestinal Cancer
Pancreatic Cancer
Colorectal Cancer
Gastroesophageal Cancer
Hepatobiliary Cancer

Can Autoimmune Diseases Increase the Risk of Digestive System Cancer?

In a systematic review and meta-analysis published in the journal eClinicalMedicine, Reizner et al highlighted bias-minimized insights into the associations between autoimmune diseases, such as celiac disease, systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes, and the risk of...

Breast Cancer

Are Postmastectomy Implant-Based Breast Reconstructions Associated With Lymphomas of the Breast?

The results of a cohort study published in JAMA Network Open revealed an epidemiologic association between postmastectomy implant-based breast reconstruction for any breast tumor and both B- and T-cell non-Hodgkin lymphomas of the breast. According to Kinslow et al, this includes diffuse large...

John C. Byrd, MD, FASCO, Named UPMC Hillman Cancer Center Director

John C. Byrd, MD, FASCO, an internationally lauded researcher and clinical specialist in hematologic malignancies, has been appointed Director of UPMC Hillman Cancer Center, effective November 2025.

In his role as Director, Dr. Byrd will be responsible for all aspects of the University of...

OHSU Knight Cancer Institute Receives $2 Billion Commitment From Phil and Penny Knight

Phil Knight, co-founder of Nike, and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s (OHSU) Knight Cancer Institute to transform the future of cancer care and set a new standard globally.

It is the largest single donation ever made to...

Solid Tumors

Dendrimer-Based SN38 Nanoparticle Shows Favorable Safety and Activity in Advanced Solid Tumors

In an early-phase study reported in the Journal of Clinical Oncology, Liu et al evaluated the safety and preliminary efficacy of DEP-SN38, a polylysine-based dendrimer-nanoparticle delivery platform for the topoisomerase 1 inhibitor SN38, in patients with advanced solid tumors. SN38 is the active...

Issues in Oncology

Patient Awareness of Pharmacogenomic Testing Remains Low, ACS CAN Survey Reports

Less than half of responding patients with cancer were previously familiar with pharmacogenomic testing and its possible benefits, according to the results of a survey conducted by the American Cancer Society Cancer Action Network (ACS CAN). Of the patients who did know about pharmacogenomic...

Prostate Cancer

PSMA PET/CT and Salvage Radiotherapy in Recurrent Prostate Cancer

Use of prostate-specific membrane antigen (PSMA) PET/CT before undergoing salvage radiotherapy was associated with an improved overall survival and biochemical recurrence–free survival compared those who did not receive PSMA PET/CT scanning in male patients with biochemically recurrent prostate...

Multiple Myeloma
Lymphoma

Rare Secondary Cancer After CAR T-Cell Therapy Successfully Treated, Case Report Shows

In a case presentation published in The New England Journal of Medicine, targeted treatment was successful for chimeric antigen receptor (CAR)-positive peripheral T-cell lymphoma developed after CAR T-cell therapy for multiple myeloma. 

Using advanced genomic, phenotypic, and functional profiling...

Breast Cancer

Endocrine Therapy With Aromatase Inhibitor for Postmenopausal Women With Breast Cancer

In a patient-level meta-analysis reported in The Lancet, Braybrooke et al of the Early Breast Cancer Trialists’ Collaborative Group found that adding subsequent years of aromatase inhibitor treatment (AIT) for women with early estrogen receptor–positive breast cancer who had already received 5...

Issues in Oncology

Can a Mitochondrial Antioxidant Drive Metastasis?

Mounting evidence suggests that the mitochondria may be a driving force behind cancer. A new report points to the mitochondrial metabolite glutathione, highlighting its central role in helping breast cancer cells break away from the primary tumor, travel through the body, and take root in other...

Lung Cancer

Effect of Hippocampal Avoidance in Prophylactic Cranial Irradiation in SCLC

In a phase II/III trial (NRG-CC003) reported in the Journal of Clinical Oncology, Gondi et al found that hippocampal avoidance (HA) in prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) did not improve delayed recall failure but was associated with benefits in...

Leukemia

Underlying Mechanisms of Chemoresistance in AML

Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cancer DiscoveryThey identified that the long-isoform RUNX1C's connection to BTG2 may enable cellular...

Advertisement

Advertisement




Advertisement